Sixth Street Specialty Lending, Inc. Provides a Letter to Stakeholders in Conjunction with its First Quarter Earnings Results
NEW YORK--(BUSINESS WIRE)--Sixth Street Specialty Lending, Inc. (NYSE: TSLX, or the 'Company') today sent the following letter to its stakeholders in conjunction with its first quarter ended March 31, 2025 financial results.
Please view a printable version of the letter here.
Source: Sixth Street Specialty Lending, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study BOSTON and LAUSANNE, Switzerland, June 10, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to initiate a Phase 1/1b study of ALY-301 in healthy volunteers and patients suffering from Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU). Cold Urticaria is a chronic skin disease where red, itchy wheals or hives appear after the skin is exposed to cold temperatures. It is a well-established clinical model for mast cell-mediated diseases in general, and chronic spontaneous urticaria in particular. Current and emerging solutions do not address the significant unmet medical needs experienced by patients. In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. ALY-301 is the first mast cell-selective c-Kit inhibitor to enter the clinic. It is a cis-targeting bispecific antibody binding c-Kit and CD-203c, allowing selective targeting and depletion of mast cells over other c-Kit positive cells. This differentiated profile of ALY-301 is expected to offer a significantly improved safety profile over conventional c-Kit targeting agents and enable safe, chronic dosing in multiple mast-cell dependent diseases such as Chronic Urticaria. The trial will evaluate the safety and efficacy of ALY-301 at multiple sites across Germany. This CTA submission is the first clinical program to emerge from Alys' Granular platform, which is focused on the precise targeting of mast cell biology through advanced antibody engineering. Professor Brian Kim, Sol and Clara Kest Professor of Dermatology and Vice Chair of Research at Icahn School of Medicine at Mount Sinai and Head of Alys Pharmaceuticals Scientific Advisory Board, said: "ALY-301 offers a truly differentiated approach. It is the only c-Kit antibody designed to target activated mast cells while avoiding off-target effects. Unleashing the proven efficacy of c-Kit inhibition on mast cells, while sparing all other cell-types that have been associated with significant side effects, should result in a transformational drug profile for ALY-301 and could have a revolutionary impact on Chronic Urticaria and several other allergic indications." Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "The concept behind ALY-301, to enable safe and effective chronic dosing of a c-Kit agent through mast-cell selectivity, has been strongly supported across all non-clinical studies. It is very exciting to start the clinical journey today, especially since this first clinical trial will yield clinical outcomes from Urticaria patients." Thibaud Portal, Co-Founder and Chief Operating Officer of Alys Pharmaceuticals, added: "Recently, there has been intense attention to solving Urticaria and other allergic diseases, with keen interest in c-Kit targeting. Data have demonstrated the remarkable potency of the mode of action, but indiscriminate c-Kit targeting has been coupled with chronic safety challenges. ALY-301 is a first-in-class approach that combines the power of c-Kit inhibition with selectivity and safety. With its expected safety margin and broad applicability across multiple diseases, this marks another pivotal moment for Alys in our journey to bring innovative treatments to patients." This study marks the second major clinical milestone for Alys Pharmaceuticals. The Alys pipeline includes a diverse portfolio of assets targeting unmet needs in indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, and systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027. About Alys PharmaceuticalsAlys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder, and COO Thibaud Portal. Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, chronic urticaria, psoriasis and mastocytosis. The Company entered the clinic in Q1 2025 with the siRNA platform developed by its affiliate Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape and is now advancing its mastocyte-selective therapies developed by affiliate Granular Therapeutics. For further information, please visit View original content: SOURCE Alys Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
35 minutes ago
- Business Wire
AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities
LONDON--(BUSINESS WIRE)--European credit specialist, AlbaCore Capital Group ('AlbaCore'), has announced the appointment of Diarmuid Curran as Managing Director and Portfolio Manager. Diarmuid Curran has joined AlbaCore as Managing Director and Portfolio Manager, bringing a wealth of experience in European credit markets to further strengthen the team and support the continued growth of the firm's European CLO platform. Diarmuid will focus on AlbaCore's leading European CLO platform – both new issuance and existing CLO fund management, reporting to Deborah Cohen Malka, Partner and Portfolio Manager, who leads the CLO business. 'I'm pleased to welcome Diarmuid to the team at AlbaCore,' said Deborah Cohen Malka. 'His background and experience will strengthen our capabilities as we continue to take advantage of the pipeline of opportunities in Europe on behalf of our investor base.' Diarmuid joins AlbaCore from Napier Park Global Capital, where he served as a Portfolio Manager. In that capacity, he was responsible for managing a portfolio of European loans and High Yield bonds held in CLOs as well as credit selection and underwriting as a member of the Investment Committee. 'I've been impressed from afar by AlbaCore's reputation in the European market,' said Diarmuid Curran. 'I look forward to working with Deborah and the team to build upon their well-established European CLO business.' In March of this year, AlbaCore successfully priced AlbaCore Euro CLO VII - it's 7 th CLO – bringing the total value of CLO platform assets under management to c. €2.9 billion. The CLO platform incorporates negative ESG screening criteria in combination with AlbaCore's fundamental research and risk focused ESG considerations, including restrictions on the industries in which the CLO can invest. About AlbaCore Capital Group AlbaCore Capital Group is one of Europe's leading alternative credit specialists, investing in private capital solutions, direct lending, opportunistic and dislocated credit, CLOs, and structured products. Founded in 2016, AlbaCore is part of the First Sentier Investors Group. AlbaCore's investment philosophy is focused on capital preservation and generating attractive risk adjusted returns through the cycle for its investors. AlbaCore manages US $10.0 billion in AuM3 as of 31 March 2025 on behalf of global pension funds, sovereign wealth funds, endowments, insurance companies, family offices and high net worths around the world.
Yahoo
41 minutes ago
- Yahoo
Vodafone Partners With ORCA Computing to Model Future Networks in Minutes Using Quantum Technology
Collaboration aims to identify best network design for customers Joint test solved mathematical network problem in minutes LONDON, June 10, 2025--(BUSINESS WIRE)--Vodafone and ORCA Computing, a leading quantum computing company, today announced a collaboration to explore the use of quantum technology in identifying the fastest and most cost-effective routes for upgrading and extending fixed and mobile broadband connections to more customers. Quantum computing has the potential to handle more complex processing tasks than a traditional computer when planning, installing and optimising large mobile radio and gigabit broadband networks. As the size and complexity of networks grow alongside demand for new digital services, Vodafone is collaborating with ORCA Computing to enhance current mathematical methods used to approximate optimal network layouts. Vodafone's software will be run on ORCA Computing's quantum computer – the ORCA PT-2 Series photonic quantum system. The solutions generated by the quantum system could, for example, help reduce total cable length and optimise the location of mobile base stations to maximise speed and minimise major civil engineering work. Vodafone will initially assess ORCA's quantum technology for solving complex optical fibre cable design challenges. Over time, Vodafone expects to use quantum principles more widely when modelling its global network which spans more than 200 destinations, including an undersea cable network transporting around 1/6 of the world's internet traffic, and a new direct-to-mobile broadband satellite communications system. The partnership with ORCA Computing, headquartered in the UK and with offices in Canada and the US, supports Vodafone's strategy to enhance and extend its networks using greater automation and powerful new computing technologies. The company anticipates that quantum computing will improve the accuracy of network optimisation, as well as accelerate the use of machine learning and Artificial Intelligence to predict faults before they impact customers. Luke Ibbetson, Head of Research & Development of Vodafone, said: "Our work with ORCA Computing aims to solve ultra-complex problems which otherwise would take many hours, weeks and even years to process on today's classical computers. Modelling new networks that maximise speed, reliability and coverage for customers, while navigating urban clutter and rural obstacles, could in future take minutes." James Fletcher, Head of Solutions Architecture at ORCA Computing, added: "ORCA Computing's continued collaboration with the Vodafone team marks an important step toward achieving practical and commercial quantum advantage. We have shown that quantum acceleration of telecommunications use cases is not just a theoretical concept, it's a viable, deployable and commercially compelling solution." The Vodafone – ORCA Computing partnership builds on the joint UK government and private sector Quantum Technology Access Programme (QTAP). At a recent QTAP event, Vodafone worked with ORCA Computing and other industry partners to quickly solve the Steiner Tree Problem, a complex mathematical challenge used today to identify the most cost-efficient way to extend connectivity. Vodafone used the ORCA PT-2 quantum computer to run an optimisation algorithm to work out a particular equation problem in minutes, paving the way for these systems to quickly solve problems that would otherwise take hours using classical computers. Notes to Editors Under the Letter of Intent (LOI), Vodafone and ORCA Computing will complement their continued research into network planning with the development of additional algorithms and well-defined test projects with specific goals and timelines. Both parties will then evaluate a deeper commercial relationship based on the results. Today's announcement supports ORCA Computing's dedication to accelerating the global adoption of quantum computing. The company continues to broaden its footprint through the deployment of PT Series quantum systems to global partners, while also leading initiatives for major government and enterprise clients. More information on Vodafone's quantum computing work can be found here: About Vodafone Vodafone is a leading European and African telecoms company. We provide mobile and fixed services to over 340 million customers in 15 countries, partner with mobile networks in over 45 more and have one of the world's largest IoT platforms. In Africa, our financial technology businesses serve almost 83 million customers across seven countries – managing more transactions than any other provider. Our purpose is to connect for a better future by using technology to improve lives, businesses and help progress inclusive sustainable societies. We are committed to reducing our environmental impact to reach net zero emissions by 2040. For more information, please visit follow us on X at @VodafoneGroup or connect with us on LinkedIn at About ORCA Computing ORCA Computing, headquartered in London, UK, with offices in the United States, is a leading developer and provider of full-stack photonic quantum computing systems. The company delivers an innovative approach to quantum computing, providing robust, high-performance, and data center-standard systems for machine learning, generative AI and optimization workloads. ORCA Computing has successfully delivered ten on-premises quantum computers to leading global customers, including the UK National Quantum Computing Centre, Montana State University, and the Poznan Supercomputing and Networking Center. For more information, please visit View source version on Contacts Vodafone Contact details: Media Relations: GroupMedia@ Investor Relations: ir@ Registered Office: Vodafone House, The Connection, Newbury, Berkshire RG14 2FN, England. Registered in England No. 1833679 ORCA Computing Media Contact: Juliet McGinnismedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
